In the STRIDE-10 study, Merck’s V116—which is a 21-valent conjugate vaccine designed for adults—stacked up favorably against ...

Pneumococcal Vaccines Market is expected to surpass US$ 13.3 Billion by 2033 to advance at a CAGR of 4.1% from 2023 to 2033.

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

Pneumococcal pneumonia can lead to worsening of pre-existing conditions, hospitalization, and even death. Alongside influenza ...

Positive findings were announced from a phase 3 trial comparing Merck’s investigational 21-valent pneumococcal conjugate vaccine, V116, to pneumococcal 23-valent polyvalent vaccine (PPSV23) in ...

Apr. 16—(StatePoint) Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt a person's life for weeks. When severe, it can result in hospitalization and even be ...

Particularly, pneumonia, a common complication of the flu caused by pneumococcal infection, is a major concern. According to the ‘2022 Cause of Death Statistics’ by the Statistics Korea, pneumonia has ...

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed ...

The phase III clinical trials of Biological E’s (BE)’s 14-Valent Pneumococcal Conjugate Vaccine (PCV), Pneubevax14 (BE-PCV-14 ...

US pharma giant Merck & Co (NYSE: MRK) has announced results from STRIDE-10, a Phase III trial of V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine (PCV), ...

Market adoption is driven by vaccine coverage, with Prevnar20 dominating with a 97% market share in adults due to its broader valency. Vaxcyte stands out with the capability to reach up to 24 ...

Report Ocean’s latest analysis delves into the “Vietnam 23 Valent Pneumococcal Polysaccharide Vaccine Market” Report from ...